Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to transform diabetes treatment in nigeria

NCT ID NCT07589387

Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test a program based on WHO guidelines to improve diabetes screening and care in 10 primary health centers in Nigeria. About 2,800 adults with or at risk for diabetes will take part. The goal is to see if the program helps more people get diagnosed and treated.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Implementation of WHO HEARTS-D guidelines (a care program, not a drug)
What this could lead to
If successful, this could show a practical way to improve diabetes diagnosis and management in low-resource settings.
What could go wrong
This is an implementation study, not a test of a new treatment. Results may not apply to other regions or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 2,800 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aim 3 Inclusion Criteria: Patients will be screened for diabetes with symptoms of hyperglycemia or BMI \>25 kg/m2 and over the age of 18 years old. Upon first or previous diagnosis, diabetes patients will be registered. * Adults (≥18 years), * Patients with previous diabetes diagnosis * Patients with persistently elevated random glucose \>200 mg/dl, fasting glucose \>126 mg/dl, or hemoglobin A1c \>6.5% on two or more occasions (when available) * Patients taking glucose lowering medications * Pregnant women are eligible for this program, or * Cognitively impaired adults are eligible for this program. Exclusion Criteria: * \- This program will not include any of the following special populations: * Individuals who are not yet adults (minors): i.e. infants, children, or teenagers \<18 years old, or * Prisoners or other detained individuals.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabete mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabete mellitus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.